| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $16.5M | — | -34.8% |
| SG&A Expense | $4.7M | — | -8.6% |
| Operating Income | -$21.1M | — | +30.4% |
| Net Income | -$20.7M | — | +28.0% |
| EPS (Basic) | -$0.33 | — | +31.2% |
| EPS (Diluted) | -$0.33 | — | +31.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $51.8M | -4.1% | +71.7% |
| Short-term Investments | $76.6M | +21.8% | -35.6% |
| Current Assets | $133.1M | +8.9% | -14.1% |
| Total Assets | $133.6M | +8.8% | -34.6% |
| Current Liabilities | $29.2M | -2.6% | +51.3% |
| Long-term Debt | $16.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$24.1M | — | +29.3% |
| Investing Cash Flow | -$13.8M | — | -148.1% |
| Financing Cash Flow | $35.7M | — | — |
| -42.7% |
| Total Liabilities | $46.2M | -11.9% | -5.7% |
| Stockholders' Equity | $87.5M | +24.2% | -43.8% |